Type 1 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Type 1 diabetes and have tested positive for certain antibodies related to the condition (antibodies against islets, insulin, IA2, GAD65, or ZnT8)
- People who use an insulin pump (a small device that delivers insulin continuously under the skin), with or without an automated insulin delivery system
- People who use a continuous glucose monitor (CGM) or a flash glucose monitor to track their blood sugar levels
- People who are willing to keep using the same type of glucose monitor throughout the one-year observation period
- People who are able to read and sign a consent form agreeing to take part in the study
Who may not be able to join:
- People who manage their insulin through multiple daily injections rather than an insulin pump, or who are not willing to wear a continuous or flash glucose monitor
- People who plan to switch to a different type of continuous glucose monitor at any point during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +41 22 372 45 90
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Correlation of 1,5-anhydroglucitol levels in newly diagnosed patients with indirect markers of beta-cell function and mass; Correlation of 1,5-anhydroglucitol levels in newly diagnosed patients with indirect markers of beta-cell function and mass; Correlation of 1,5-anhydroglucitol levels in newly diagnosed patients with indirect markers of beta-cell function and mass; Correlation of 1,5-anhydroglucitol levels in patients with longstanding disease with indirect markers of beta-cell function and mass; Correlation of 1,5-anhydroglucitol levels in patients with longstanding disease with indirect...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.